Anti-fungal composition
View Patent ↗An anti-fungal product for delivering at least two different anti-fungals that is comprised of three dosage forms with different release profiles with each anti-fungal being present in at least one of the dosage forms.
1. A once-a-day anti-fungal product comprising: first, second, and third dosage forms, wherein each of said dosage forms includes at least one anti-fungal agent and a pharmaceutically acceptable carrier; wherein at least one of said dosage forms includes at least a first anti-fungal agent and wherein at least one of said dosage forms includes at least a second anti-fungal agent, said second anti-fungal agent being different than said first anti-fungal agent; said first dosage form is an immediate release dosage form; said second and third dosage forms are delayed release dosage forms; each of said first, second, and third dosage forms initiates release of the anti-fungal agent(s) at different times; the Cmax in serum of the total anti-fungal agents released from said anti-fungal product is achieved in less than about 12 hours from administration; said once-a-day anti-fungal product contains the total dosage of said at least two different anti-fungal agents for a twenty-four hour period, and wherein at least one of said three dosage forms contains both the first and the second anti-fungal agents.
2. The product of claim 1 , wherein anti-fungal released from the second dosage form reaches a Cmax in serum afier anti-fungal released from the first dosage reaches a Cmax in serum.
3. The product of claim 2 , wherein anti-fungal released form the third dosage form reaches a Cmax in serum after anti-fungal released from the second dosage form reaches Cmax in serum.
4. The product of claim 1 , wherein each of the three dosage forms includes at least the first and second anti-fungals.
5. The product of claim 1 , wherein the first dosage form includes the first anti-fungal, the second dosage form includes the first and second anti-fungals, and the third dosage form includes the second anti-fungal.
6. The product of claim 1 , wherein the immediate release dosage form contains from 20% to 50% of the total dosage of anti-fungal.
7. The product of claim 1 , wherein said second dosage form initiates release of anti-fungal before said third dosage form, wherein said second dosage form provides from 30% to 60% by weight of the total anti-fungal released by said second and third dosage forms, and wherein said third dosage form provides the remainder of the total anti-fungal released by said second and third dosage forms.
8. The product of claim 1 , wherein anti-fungal released from the second dosage form reaches a Cmax in serum in no more than about 4 hours after administration of the product.
9. The product of claim 1 , wherein anti-fungal released from the third dosage form reaches a Cmax in serum within 8 hours after administration of the product.
10. The product of claim 1 , wherein the product is an oral dosage form.
11. The product of claim 1 further comprising: a fourth dosage form, and wherein said first dosage form contains said first anti-fungal; said second dosage form contains said first anti-fungal; said third dosage form contains said second anti-fungal; said fourth dosage form includes said second anti-fungal and a pharmaceutically acceptable carrier; and said second and third dosage forms have release profiles whereby C max in serum for the first anti-fungal and C max in serum for the second anti-fungal released from the second and third dosage forms respectively are reached later in time than C max in serum is reached for the first anti-fungal released from the first dosage form, and whereby the C max in serum for the second anti-fungal released from the fourth dosage form is reached at a time after C max in serum for anti-fungal released from each of the first, second, and third dosage forms are reached.
12. The product of claim 11 , wherein the first anti-fungal released from the second dosage form, and the second anti-fungal released from the third dosage form reach a C max in serum at about the same time.
13. The product of claim 11 , wherein said fourth dosage form is a sustained release dosage form.
14. The product of claim 11 , wherein said fourth dosage form is a delayed release dosage form.
15. The product of claim 14 , wherein the immediate release dosage form contains from 15% to 30% of the total dosage of anti-fungal.
16. The product of claim 14 , wherein said second dosage form initiates release of anti-fungal before said third dosage form; wherein said third dosage form initiates release of anti-fungal before said fourth dosage form; wherein said second dosage form provides 20% to 35% by weight of the total anti-fungal released by said second, third, and fourth dosage forms; wherein said third dosage form provides from 20% to 40% by weight of the total anti-fungal released by said second, third, and fourth dosage forms; and wherein said fourth dosage form provides the remainder of the total anti-fungal released by said second, third, and fourth dosage forms.
17. The product of claim 11 , wherein anti-fungal released from the second dosage form reaches a Cmax in serum in no more than about 4 hours after administration of the product.
18. The product of claim 11 , wherein anti-fungal released from the third dosage form reaches a Cmax in serum within 8 hours after administration of the product.
19. The product of claim 11 , wherein the product is an oral dosage form.
20. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 1 once-a-day.
21. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 2 once-a-day.
22. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 3 once-a-day.
23. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 4 once-a-day.
24. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 5 once-a-day.
25. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 6 once-a-day.
26. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 7 once-a-day.
27. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 8 once-a-day.
28. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 9 once-a-day.
29. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 10 once-a-day.
30. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 11 once-a-day.
31. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 12 once-a-day.
32. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 13 once-a-day.
33. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 14 once-a-day.
34. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 15 once-a-day.
35. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 16 once-a-day.
36. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 17 once-a-day.
37. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 18 once-a-day.
38. A process for treating a fungus infection in a host comprising:
administering to the host the anti-fungal product of claim 19 once-a-day.
39. A process for treating a patient with two different anti-fungal agents said process for treating comprising:
administering to a patient once-a-day an anti-fungal product, said product comprising: first, second, and third dosage forms, wherein each of said dosage forms includes at least one anti-fungal agent and a pharmaceutically acceptable carrier; wherein at least one of said dosage forms includes at least a first anti-fungal agent and wherein at least one of said dosage forms includes at least a second anti-fungal agent, said second anti-fungal agent being different than said first anti-fungal agent; wherein at least one of said three dosage forms contains both the first and the second anti-fungal agents said treating including an immediate release of anti-fungal agent from said first dosage form and delayed releases of anti-fungal agent from each of said second and third dosage forms, said immediate release and two delayed releases initiating release of anti-fungal agent at different times and achieving the Cmax in serum of the total anti-fungal agents released from said anti-fungal product in less than about 12 hours from administration; and said treating delivers the total dosage of said first and second anti-fungal agents for a twenty-four hour period.